The Safety and Efficacy of Preoperative Immunotherapy Combined with Chemotherapy in Patients with Stage IIIA-IIIB Lung Squamous Cell Carcinoma

Abstract

Objective Data on preoperative immunotherapy combined with chemotherapy in potentially resectable lung squamous cell carcinoma (LUSC) remain scarce. This study was designed to investigate the safety and efficacy of preoperative immunotherapy and chemotherapy for stage IIIA-IIIB LUSC. Methods This study consecutively enrolled stage IIIA-IIIB LUSC who received preoperative immunotherapy combined with chemotherapy between January 2019 and July 2021. Patients received two to four cycles of immunotherapy combined with platinum-based doublet chemotherapy (platinum + paclitaxel) before surgery. Patients were assessed radiographically every one to two cycles until surgery. Postoperative pathological evaluation was also performed. Follow-up was performed until at least 3 months after surgery. Results Sixty-five patients with stage IIIA-IIIB LUSC were enrolled. The objective response rate was 78.46% (51/65), and no patients had progressive disease. Fifty-seven patients underwent surgery, and 55 patients achieved R0 resection. There were no perioperative deaths. The rate of pathological complete response (pCR) was 31.58% (18/57) and major pathological response was 68.42% (39/57). The incidence of grade 3 and 4 adverse reactions was 21.21 and 1.54%, respectively. Conclusion Perioperative immunotherapy combined with chemotherapy followed by surgical resection for male patients with stage IIIA-IIIB LUSC was effective with a tolerable toxicity profile.

Exploration on Short Term Efficacy and Safety of PD-1 Immunotherapy Combined with Neoadjuvant Chemotherapy in the Treatment of Non-small Cell Lung Cancer

“…Based on the imaging data before and after chemotherapy, evaluate the efficacy of chemotherapy according to the Solid Tumor Efficacy Evaluation Standard 1.1 (RECIST 1.1), and record the objective response rate [2,8]. According to the effectiveness of treatment, it can be divided into: progressive disease (PD), stable disease (SD), partial response (PR), and complete response (CR).…”

“…Retrospective analysis of the clinical data of 89 non-small cell lung cancer patients who underwent PD-1/PD-L1 immunotherapy combined with neoadjuvant chemotherapy from January 2020 to December 2022 in the first and second extrathoracic wards of our hospital. Inclusion criteria: (1) Confirmed as NSCLC through pathological examination, with clinical diagnosis staging ranging from stage IA to stage IIIB; (2) No distant metastasis of lung cancer has occurred yet; (3) Patients receiving PD-1/PD-L1 immune combined with neoadjuvant chemotherapy treatment plan; (4) The Eastern Cooperative Oncology Group (ECOG) in the United States has a score of 0-1; (5) At least 1 measurable lesion in imaging; (5) Eliminate severe liver, kidney, heart, and lung dysfunction; (6) Sign an informed consent form. Exclusion criteria: (1) Individuals who are physically weak and unable to tolerate surgery or patients with severe systemic diseases or severe organ dysfunction; (2) There are contraindications to using immune checkpoint inhibitors; (3) The presence of sensitive gene mutations is not suitable for immunotherapy.…”

“…At present, the incidence rate and mortality of lung cancer in the world are increasing year by year, and it is one of the most common and Case fatality rate malignant tumors in the world [1]. According to the relevant data released by the International Agency for Research on Cancer in 2020, lung cancer ranks second in the incidence rate of malignant tumors, but the number of deaths caused by lung cancer each year ranks first [2]. According to the pathological classification of cancer cells, primary lung cancer can be classified as non-small cell lung cancer (Non small cell lung cancer, NSCLC) and small cell lung cancer (SCLC), among which NSCLC is the most common type of lung cancer, accounting for approximately 85% of the total primary lung cancer [2].…”

“…According to the relevant data released by the International Agency for Research on Cancer in 2020, lung cancer ranks second in the incidence rate of malignant tumors, but the number of deaths caused by lung cancer each year ranks first [2]. According to the pathological classification of cancer cells, primary lung cancer can be classified as non-small cell lung cancer (Non small cell lung cancer, NSCLC) and small cell lung cancer (SCLC), among which NSCLC is the most common type of lung cancer, accounting for approximately 85% of the total primary lung cancer [2]. The main pathological types of NSCLC include adenocarcinoma, squamous cell carcinoma, large cell lung cancer, and other rare types of lung cancer [3].…”